February 23-25, 2027 | Boston, MA

www.targeted-radiopharma-target-selection-drug-design.com

REGISTER BY FRIDAY, NOVEMBER 20 & SAVE UP TO $800

3rd Annual

TRP Target Selection & Drug Design Summit

Designing the Next Generation of Radiopharmaceutical Pipelines

Evaluating Novel Target Trial Data, Isotope Selection, Dosimetry Assessment, & Sharing Regulatory Insights to Drive & Achieve RLT Potential as First-Line & Combination Therapies in Modern Oncology

Expert Speakers Include:



Charles Glaus
Senior Director, Oncology Precision Medicine & Early Clinical Development
Bayer



Marianna Stamou
Director, Project Toxicologist
AstraZeneca



Anneli Savinainen
Vice President & Head of Preclinical Development
Mariana Oncology



Daniel Steiner
Senior Vice President, Targeted Radio Therapeutics
Molecular Partners



Shadi Esfahani
Professor of Radiology, Director of Molecular Theranostics Laboratory
Harvard Medical School



Bob Seevers
Regulatory Consultant, Ex-FDA
Independent

Proud to Partner With:

Macrocyclics™ perceptive Chelatec

+1 617 455 4188 info@hansonwade.com TRP Event Series
www.targeted-radiopharma-target-selection-drug-design.com
hansonwade

The Industry-Dedicated, Radiopharma, Discovery & Preclinical Forum

3rd Annual TRP Target Selection & Drug Design Summit
February 23-25, 2027 | Boston, MA

As established targets such as PSMA become increasingly crowded, attention is shifting towards novel targets, new disease settings and differentiated candidates driving the next wave of clinical success. For early-stage teams, success is being determined earlier in development, whether an RLT will be shelved or make it to the clinic.

If you're working to **push a candidate towards the clinic, expand your target landscape, mine other modalities for clinically validated targets, select the right radionuclide, navigate preclinical packages or understand toxicity**, this is where those conversations happen.

The **3rd TRP Target Selection & Drug Design Summit** is purpose built to help drug developers confidently prioritize the strongest RLT candidates. Learn from 100+ experts including Bayer, AstraZeneca, Pfizer, Regeneron, Molecular Partners, United Therapeutics, Mariana Oncology and Ex-FDA to benchmark the science shaping the next generation of RLT pipelines.

- For **Discovery**, **Biology**, **Medicinal Chemistry**, **Radiochemistry**, **ADME/DMPK, Toxicology**, **Radiobiology**, and **Dosimetry Experts** the meeting addresses the scientific challenges shaping the future of RLT discovery from identifying novel targets and navigating the Alpha vs Beta debate, to optimizing targeting moieties, linkers, chelators and biodistribution to engineer safer, more effective and more differentiated radiopharmaceuticals.
- For **CEOs**, **Corporate Development**, and **Business Development** leaders, to understand where the next wave of radiopharmaceutical value creation will come from, benchmark emerging approaches, and identify the targets, isotope strategies and drug design innovations most likely to create meaningful competitive differentiation.

What The Attendees Have to Say

"While everyone came with a different perspective, there was a real sense that everyone was prepared to discuss the key issues facing our field in a productive manner."

Past Attendee, Director, AstraZeneca

"I liked the balance of having both preclinical and clinical speakers that could give an overall picture of the challenges that come with RLTs"

Past Attendee, Senior Scientific Lead, ADME & DMPK, Eli Lilly

Key Benefits of Attending



Harness **kinetic imaging**, total-body PET, computational biology & digital SPECT to **generate richer target characterization** and translational insights increasingly demanded by the FDA, with **United Theranostics** & **University of Pennsylvania**



Mine clinically validated targets from **ADCs**, **RDCs** & **combination modalities** to de-risk target selection and prioritize those with greater potential for clinical translation, with insights from **Pfizer** & **Vitsgen Therapeutics**



Interrogate emerging targets across **CAIX**, **MSLN**, **the brain**, **ECM** & **leukocytes** to determine how expression, replenishment & internalization influence suitability for radiopharmaceutical development with **Mariana Oncology** & **Matrisome Bio**



Build robust preclinical safety packages through organ-specific risks, **dose-limiting toxicities** and translational considerations to strengthen confidence ahead of the clinic, with insights from **AstraZeneca** & **Osaka University**



Determine when a **lean versus comprehensive preclinical package** is enough to progress confidently towards the clinic, with expert guidance from a former FDA expert & real-world development insights from **Ratio Therapeutics** & **Bayer**

The Landscape Is Changing
So Are We
Here's What's New For 2027

3rd Annual TRP Target Selection & Drug Design Summit
February 23-25, 2027 | Boston, MA

A Rapidly Expanding RLT pipeline

298 preclinical programs


176 clinical programs

3 approved therapies

The RLT landscape continues to accelerate, with 298 preclinical programs globally, highlighting both the opportunity and increasing need to target differentiation.

As more programs compete across a concentrated set of established targets, this meeting provides you with the tools to define next-generation RLT programs earlier in development

Top Targets in Active Preclinical Development to Approval*



Programs are currently concentrated around a limited number of targets, creating a clear need to explore new sources of target opportunity.

* Does not include 156 undisclosed targets (Beacon Data)

So, What's New?

New Workshop

Mining Clinically Validated Targets for RLT to De-Risk & Accelerate Target Selection

Validating novel targets remains costly and time-consuming, while a wealth of clinical evidence already exists across other targeted therapies. This workshop will explore how to assess targets validated outside radiopharmaceuticals and determine when there is sufficient evidence to justify progression into an RLT program.



ADCs | T-Cell Engagers | Cell Therapies | Targeted Antibodies | Molecular Imaging | RDCs

New Workshop

Harnessing Kinetic Imaging for Characterizing Emerging Targets and Securing Validation



PET & SPECT imaging have long helped identify promising radiopharmaceutical targets. Advances in multi-omics, computational biology and quantitative imaging are providing richer insight into target expression, heterogeneity and *in vivo* behavior over time. This workshop will explore how these approaches can be combined to distinguish interesting biological targets, and those that simply image well, from those most likely to translate into effective therapeutics.

Total Body PET | Digital SPECT | Axial Field of View | Computational Biology

Unrivalled Networking With 100+ Experts Across The Preclinical RLT Ecosystem

Meet and benchmark with the teams selecting targets, designing candidates and progressing them towards the clinic.



Maximize Every Connection

Speed Networking
By the first break on Day One, meet everyone in the room through this dedicated high-volume networking session.

Poster Session
Discover tomorrow's breakthroughs today and get extra presentation time in front of the entire audience and speaker faculty.

Breakfasts, Lunch & Coffee Breaks
Start conversations, share ideas and make connections.

New Companies to the 2027 Speaker Faculty

FORMER FDA.com | Matrisome Bio | 大阪大学 OSAKA UNIVERSITY | Penn | AFFIBODY
MOLECULAR partners | iSeek BIOPHARMA | HARVARD MEDICAL SCHOOL | Ratio THERAPEUTICS | Convergent THERAPEUTICS
dGT | Thomas Jefferson University | United Theranostics

+1 617 455 4188 | info@hansonwade.com | TRP Event Series
www.targeted-radiopharma-target-selection-drug-design.com
hansonwade

Your Expert Speakers

Regulatory Voice



Bob Seevers
Regulatory Consultant, Ex-FDA
Independent

Big Pharma Specialists



Anneli Savinainen
Vice President & Head of Preclinical Development
Mariana Oncology/ Novartis



Charles Glaus
Senior Director, Oncology Precision Medicine & Early Clinical Development
Bayer



Marianna Stamou
Director, Project Toxicologist
AstraZeneca



Vamsi Parimi
Medical Director, ADC Biomarkers
Pfizer (Former)

Leading Biotech Experts



Anthony Casarez
Co-Founder & Chief Scientific Officer
dGenThera



Daniel Steiner
Senior Vice President, Targeted Radio Therapeutics
Molecular Partners



Fredrik Frejd
Chief Scientific Officer
Affibody AB



Jack Hoppin
Chief Executive Officer
Ratio Therapeutics, Inc.



Jeff Norenberg
Founder, CEO and Chairman
iSeek Biopharma



Keene Wei
Chief Executive Officer
Vitsgen Therapeutics



Monica Gostissa
Chief Scientific Officer
Matrisome Bio



Munir Ghesani
Chief Medical Officer
United Theranostics



Riccardo Canevari
Chief Executive Officer
RadioPharm Theranostics



Shankar Vallabhajosula
Vice President, Radiopharmaceutical Sciences
Convergent Therapeutics, Inc.



Sofia Santos
Head of Biology
Nuclide Therapeutics

Academic All-Stars



David Mankoff
Professor, Radiology
University of Pennsylvania



Elisabeth Li
PET Center Advanced Image Analysis Lab Lead
University of Pennsylvania



Mathew Thakur
Director, Radiopharmaceutical Research
Thomas Jefferson University



Quaovi Sodji
Assistant Professor
University of Wisconsin-Madison



Shadi Esfahani
Professor of Radiology, Director of Molecular Theranostics Laboratory
Harvard Medical School



Tadashi Watabe
Associate Professor
Osaka University

Patient Advocate



Jean-Luc Vanderheyden, PhD
Executive Director
Oncidium Foundation USA

Pre-Conference Workshop Day
Tuesday, February 23

Morning Registration & Breakfast 8.00

Chair's Opening Remarks 8.55

Workshop A 9.00-12.00


Harnessing Kinetic Imaging: Integrating AFOV, Computational Biology, & TB PET& Digital SPECT to Identify and Characterize Emerging Targets with the Greatest Therapeutic Potential

PET & SPECT imaging have long helped identify promising radiopharmaceutical targets. Advances in multi-omics, computational biology and quantitative imaging are providing richer insight into target expression, heterogeneity and *in vivo* behavior over time.


This workshop will explore how these approaches can be combined to distinguish interesting biological targets, and those that simply image well, from those most likely to translate into effective therapeutics.

- Identifying & prioritizing higher-potential targets: Integrating multi-omics and computational biology to assess tumor-to-healthy expression, prevalence, heterogeneity and therapeutic potential before progressing a target
- Looking beyond high tumor uptake: Determining whether a target that looks promising on an initial scan has the biological characteristics required for effective radiopharmaceutical therapy
- Understanding target behavior over time: Using longitudinal PET & SPECT to assess target engagement, retention, washout, clearance and tumor vs healthy-tissue biodistribution
- Building higher-confidence target go/no-go decisions: Combining computational, biological, and human imaging evidence to distinguish targets that simply look promising from those most likely to translate into effective therapeutics

Workshop Leaders



Munir Ghesani
Chief Medical Officer
United Theranostics



Elisabeth Li
PET Center Advanced Image Analysis Lab Lead
University of Pennsylvania

Lunch Break 12.00

Workshop B 1.00-4.00

Leveraging ADC, RDC, Immuno-oncology, & CDx Clinical Validation to Identify & Progress High-Potential RLT Targets Faster

Validating novel targets remains costly and time-consuming, while a wealth of clinical evidence already exists across ADCs, T-cell engagers, bispecifics and other targeted therapies.

This workshop will explore how to assess targets validated outside radiopharmaceuticals and determine when there is sufficient evidence to justify progression into an RLT program.

- Mining other modalities for targets: What can we learn from ADCs, T-cell engagers, bispecifics, and other targeted therapies to identify clinically validated targets with potential for RPT?
- Determining what translates: Which target characteristics and clinical data are genuinely transferable, and where do RPT requirements diverge across target accessibility, expression density, internalization, heterogeneity, biodistribution, and normal-tissue uptake?
- Building a cross-modality target-selection framework: Define the evidence required to confidently progress a clinically validated target into RPT, identify the additional RPT-specific validation needed and establish clear go/no-go criteria before committing significant time and investment

Workshop Leaders



Quaovi Sodji
Assistant Professor
University of Wisconsin-Madison



Keene Wei
Chief Executive Officer
Vitsgen Therapeutics, Inc.



Vamsi Parimi
Medical Director, ADC Biomarkers
Pfizer (Former)

Chair's Closing Remarks 4.00

Conference Day One
Wednesday, February 24

7.30 **Morning Registration & Breakfast**

8.15 **Ice Breaker**

Break the ice before the science begins. Join your table for a light hearted, TRP-themed networking activity designed to get conversations flowing, strengthen connections and maximize your networking opportunities throughout the summit.

8.25 **Chair's Opening Remarks**

Identifying & Prioritizing Emerging Targets to Expand the RLT Landscape & Unlock New Therapeutic Opportunities



Keene Wei
Chief Executive Officer
Vitsgen Therapeutics, Inc.

8.30 **Expanding the RLT Target Landscape: From Novel Target Selection to Candidate Optimization**

- Explore the rationale for selecting novel targets with therapeutic potential beyond established RLT targets
- Apply lessons learned from advancing PSMA and FAP programs into clinical development to inform target selection and candidate optimization
- Leverage insights from PSMA and FAP around affinity, internalization, tumor uptake and retention to guide the design of next-generation candidates



Daniel Steiner
Senior Vice President, Targeted Radio Therapeutics
Molecular Partners
Novel Target

9.00 **Understanding Dynamic Target Expression Beyond Receptor Density to Expand the Pool of Viable RLT Targets**

- Challenging static receptor-density thresholds to prevent promising therapeutic targets being ruled out too early
- Understanding internalization & receptor replenishment to determine how lower-density targets can still deliver sufficient radiation to the tumor
- Redefining "good enough" target expression to identify a broader range of viable targets for RLT development



Jeff Norenberg
Founder, CEO and Chairman
iSeek Biopharma
Novel Target

9.30 **Targeting Immune Biology Beyond the Tumor Cell: Unlocking LFA-1 for Radiopharmaceutical Development**

- Explore LFA-1 on leukocytes as an emerging target to move beyond conventional tumor-cell receptor expression
- Harness innate immune biology and leukocyte activity within the tumor environment to identify new opportunities for targeted imaging and therapy
- Translate LFA-1-targeted ligands from imaging into therapeutic applications, leveraging early clinical validation to inform next-generation development

10.00 **Introduction to Speed Networking**

10.05 **Speed Networking**

A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the Summit.

10.45 **Morning Break & Networking**



Monica Gostissa
Chief Scientific Officer
Matrisome Bio
Novel Target

11.00 **Targeting the Extracellular Matrix to Increase Tumor Retention & Expand RLT Across Cancer Types**

- Targeting abundant ECM components beyond tumor-cell receptors to reduce dependence on variable or low receptor expression
- Exploiting tumor-specific ECM accumulation & accessibility to deliver and retain greater radioactive retention within the tumor
- Identifying conserved ECM targets across tumor types to unlock RLT opportunities across primary & metastatic disease

Conference Day One
Wednesday, February 24

Strengthening Target Validation to Select the Most Promising Biology & Increase Confidence in Clinical Translation



Shadi Esfahani
Professor of Radiology, Director of Molecular Theranostics Laboratory
Harvard Medical School
Novel Target

11.30 Closing the Research-to-Clinic Gap: Building the Evidence to Translate an Academic Target into RLT Development

- Validating promising academic biology in increasingly translational models to establish whether the target is robust enough for drug development
- Identifying the critical experiments that increased or challenged confidence to determine when continued investment was justified
- Bridging academic discovery & industry validation requirements to build an evidence package capable of progressing a novel target towards the clinic



Jack Hoppin
Chief Executive Officer
Ratio Therapeutics

12.00 Roundtable Discussion: Defining the RLT Target Validation Package to Determine When the Biology Strong Enough to Progress to the Clinic

- Validating tumor-to-healthy expression, prevalence, & heterogeneity to confirm the target is sufficiently selective and consistent to progress
- Assessing accessibility, internalization, replenishment, & density to prove the target can support meaningful radionuclide delivery
- Defining the minimum *in vitro*, *in vivo* & imaging evidence to make earlier, higher-confidence target go/no-go decisions

12.30 Lunch Break & Networking



Riccardo Canevari
Chief Executive Officer
RadioPharm Theranostics
Novel Target

1.30 Validating Targets in the Brain: Using Imaging to Build Confidence in Therapeutic Potential

- Use brain metastases as a clinical case study to understand target accessibility, engagement, and biodistribution within the challenging brain environment
- Leverage clinical imaging to determine whether a targeting agent can reach and sufficiently accumulate within brain lesions
- Translate lessons from imaging into target-validation criteria for therapeutic development, while accounting for the different requirements of imaging and RLT

Optimizing Drug Design to Maximize Tumor Delivery & Retention While Minimizing Healthy-Tissue Exposure



Anthony Casarez
Chief Scientific Officer
dGenThera

2.00 Engineering High-Fidelity Theranostic Pairs with Covalent Radiohalogens (F-18/I-131/At-211) to Improve Biodistribution, Tumor Retention & Clinical Translation

- Designing covalent radiohalogen therapeutics with matched diagnostic–therapeutic pairs to improve predictive biodistribution and translational confidence
- Overcoming traditional limitations of chelated radiometals by reducing off-target accumulation and enabling blood-brain barrier penetration
- Presenting preclinical imaging and efficacy data showing remarkable tumor control and favorable safety profiles across small molecule and bioligand-tagged platforms



Fredrik Frejd
Chief Scientific Officer
Affibody AB

2.30 Matching Target, Molecule & Radionuclide to Improve Biodistribution

- Understand how target biology and molecular format should inform early radiopharmaceutical design decisions
- Optimize Affibody-based targeting agents, chelators and radionuclide selection to improve biodistribution and tumor targeting
- Apply successes and failures from candidate development to identify which design characteristics are most likely to translate

Conference Day One
Wednesday, February 24



Anneli Savinainen
Vice President & Head of Preclinical Development
Mariana Oncology
Novel Target

3.00 Optimizing a DLL3-Targeted Radiotherapeutic Through Preclinical Development

- Explore the preclinical development of a DLL3-targeted radiotherapeutic from candidate design through efficacy evaluation
- Assess how biodistribution, tumor uptake & retention inform optimization of radiotherapeutic performance
- Leverage preclinical findings to guide candidate selection & progression towards clinical development



3.30 Afternoon Break & Poster Session

A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the Summit.

To submit a poster please reach out to poster@hansonwade.com

Matching Radionuclides to Tumor Biology to Maximize Disease Coverage & Therapeutic Effect



Anthony Casarez
Chief Scientific Officer
dGenThera

4.30 Comparing Alpha vs Beta Radiation Range & Energy to Tumor Biology to Maximize Disease Coveragee

- Assessing tumor size, architecture & target heterogeneity to determine whether short-range alpha or longer-range beta irradiation provides better disease coverage
- Leveraging beta crossfire or high-LET alpha irradiation to overcome differences in target density & spatial distribution
- Matching radionuclide half-life & dose rate to vector PK and tumor residence to ensure radiation is delivered while the targeting agent remains at the tumor



Tadashi Watabe
Associate Professor
Osaka University
Novel Target

5.00 Translating Astatine-211 Targeted Alpha Therapy From Preclinical Development to First-in-Human Studies

- Translate novel At-211 compounds from discovery through preclinical development, examining the studies required to build confidence ahead of clinical translation
- Navigate preclinical toxicity & translational considerations when progressing an At-211 program towards FIH evaluation
- Share lessons from investigator-initiated Phase I development to identify what early-stage RLT developers should consider when designing the next generation of alpha-emitting therapeutics

5.30 Chair's Closing Remarks

5.35 End of Scientific Day One

"From my point of view speakers and companies attending the conference were very well picked. Also, the scope of the conference with a rather selected number of attendants generated a nice, familiar atmosphere. It gave a good possibility to connect with people in the field. Also, the talks were nicely picked and aligned in the conference program"

Past Attendee, Director, Program Management, PentixaPharm

Conference Day Two
Thursday, February 25

8.00 **Morning Registration & Breakfast**

8.55 **Chair's Opening Remarks**

Advancing Preclinical Models to Generate More Human-Relevant Evidence & Better Predict Clinical Performance

9.00 **Keeping the Patient in Mind: Building Preclinical Evidence That Better Supports Translation into Humans**



Jean-Luc Vanderheyden, PhD
Executive Director
Oncidium Foundation USA

- Work backwards from the intended patient population and clinical setting to determine which preclinical questions need to be answered before progressing an RLT towards human studies
- Interrogate where preclinical models accurately reflect human disease and where they fall short, using complementary evidence to strengthen confidence in translation
- Apply lessons from previous RLT development to generate preclinical evidence that better informs clinical study design, treatment delivery and the successful progression of next-generation candidates into patients

9.30 **Building Preclinical Models that Better Recapitulate Human RLT Biology to Improve Prediction of Clinical Performance**

Reserved for AstraZeneca

- Selecting models that reproduce clinically relevant target expression, heterogeneity & tumor biology to generate more representative preclinical data
- Identifying where conventional xenografts misrepresent human disease to avoid overestimating candidate performance
- Defining the characteristics required of a predictive model to support higher-confidence candidate progression

10.00 **Fireside Chat: How Much Preclinical Evidence Is Enough?: Defining a Fit-for-Purpose Preclinical Package to Progress RLTs Towards IND**

- Benchmark contrasting approaches to preclinical development to determine the level of evidence required to progress confidently towards the clinic
- Determine which studies generate decision-critical evidence versus where additional data adds time, cost, & complexity without strengthening the development case
- Balance toxicology, biodistribution, dosimetry, pharmacology, & model selection to build a robust package proportionate to the candidate and development stage
- Leverage early FDA engagement to clarify expectations, ask the right scientific questions, & establish a more predictable path towards IND



Anneli Savinainen
Vice President & Head of Preclinical Development
Mariana Oncology



Charles Glaus
Senior Director, Oncology Precision Medicine & Early Clinical Development
Bayer



Bob Seevers
Regulatory Consultant, Ex-FDA
Independent

10.30 **Morning Break & Networking**

Understanding Radiobiology to Translate Radiation Dose into Therapeutic Response & Maximize Treatment Effect

11.30 **Understanding Radiobiological Drivers Beyond Absorbed Dose to Strengthen RLT Candidate Selection**



Sofia Santos
Co-Founder & Head of Biology
Nuclide Therapeutics

- Interrogate cellular uptake and target-specific biology to understand how biological characteristics influence therapeutic response beyond absorbed dose alone
- Leverage knockout and knock-in models alongside in vitro and in vivo validation to establish target-specific effects and strengthen confidence in the underlying biology
- Integrate imaging and therapy studies throughout preclinical development to connect biological response with candidate performance and inform progression towards the clinic

Conference Day Two
Thursday, February 25



David Mankoff
Professor, Radiology
University of Pennsylvania

12.00 Connecting Subcellular Localization & Radiation Quality to Better Predict Therapeutic Potency

- Understand how subcellular localization changes biological response, even when absorbed dose appears comparable at the organ or tissue level
- Examine how the type and range of radiation interact with localization to influence therapeutic effect and normal-tissue toxicity
- Integrate localization, radiation biology, and dosimetry to improve prediction of the therapeutic window during translation

12.30 Roundtable Discussion: Harnessing Short-Lived Alpha Emitters to Maximize the Therapeutic Benefit of Combination Strategies

- Understanding how short, high-intensity alpha irradiation alters tumor biology to identify opportunities for synergistic combination therapies
- Combining alpha therapy with immunotherapy & other treatment modalities to enhance anti-tumor response beyond RLT alone
- Optimizing isotope half-life, treatment timing, & sequencing to maximize the therapeutic benefit of combination strategies

1.00 Lunch Break & Networking

Advancing Dosimetry to Define the Therapeutic Window, Guide Candidate Selection, & Inform Clinical Dosing



Shankar Vallabhajosula
Vice President, Radiopharmaceutical Sciences
Convergent Therapeutics

2.00 Comparing Dosimetry Considerations Across Alpha & Beta Emitters to Inform Therapeutic Development

- Benchmark the current state of therapeutic radiopharmaceutical dosimetry to understand what can reliably be measured today & where critical uncertainties remain
- Examine current regulatory expectations & the limitations of existing dose thresholds to determine what evidence is needed for therapeutic radiopharmaceutical development
- Explore the path towards more standardized dosimetry approaches that can better connect absorbed dose with clinical outcomes & inform therapeutic development

2.30 Roundtable Discussion: Connecting Macro & Micro Dosimetry to More Accurately Characterize Tumor & Healthy-Tissue Radiation Exposure

- Identifying what whole-organ absorbed dose fails to capture to reveal important differences in radiation exposure
- Accounting for heterogeneous radionuclide distribution at tissue & cellular levels to understand where average dose may mask localized dose variation
- Applying microdosimetry where greater resolution is needed to more accurately characterize the dose delivered to tumor & healthy tissue



Charles Glaus
Senior Director, Oncology Precision Medicine & Early Clinical Development
Bayer

3.00 Integrating Dosimetry, PK & Biodistribution to Improve Human Dose Prediction & Inform Clinical Progression

- Combining imaging-derived kinetics, PK & biodistribution data to build more robust human dose predictions
- Accounting for species differences in distribution, clearance, & organ kinetics to improve extrapolation from animals to humans
- Quantifying uncertainty in predicted tumor & organ doses to determine when estimates are reliable enough to support clinical progression

Conference Day Two
Thursday, February 25

3.30 **Afternoon Break & Networking**

Strengthening Safety Prediction to Characterize Toxicity & Maximize the Achievable Therapeutic Window



Marianna Stamou
Director, Project Toxicologist
AstraZeneca

4.30 **Defining the Non-Clinical Safety Strategy for Next-Generation Radiopharmaceuticals**

- Navigate differences in non-clinical safety requirements across regulatory regions to understand what evidence is needed to progress towards FIH
- Tailor the safety strategy to the target, modality, and radioconjugate profile, rather than applying a one-size-fits-all toxicology package
- Identify the remaining safety uncertainties after IND-enabling studies and determine where additional evidence is needed to better predict clinical risk



Mathew Thakur
Director, Radiopharmaceutical Research
Thomas Jefferson University

5.00 **Improving RLT Safety & Reducing Off-Target Toxicity Through Tumor-Selective Targeting**

- Identify biomarkers preferentially expressed on malignant versus healthy cells to strengthen tumor selectivity & minimize normal-tissue exposure
- Leverage molecular imaging to characterize target expression & tumor uptake and inform suitability for therapeutic development
- Translate diagnostic targeting insights into therapeutic radiopharmaceutical strategies to improve specificity & reduce off-target toxicity
- Apply lessons across prostate, breast, & bladder cancer to demonstrate how tumor-selective targeting can support safer therapeutic development

5.30 **Chairs Closing Remarks**

5.35 **End of 3rd TRP Target Selection & Drug Design Summit**

> "Positive experience. Good size of conference to allow for meaningful conversations and workshops. Very engaged crowd"
>
> Past Attendee, Principal Scientist - Medicinal Chemistry, **Bicycle Therapeutics**

2027 Partners

Exhibition Partner

Macrocyclics, Inc. is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. A subsidiary of Orano Med, the company provides custom synthesis, kilo-scale manufacturing, and bioconjugation services to accelerate early-stage pharmaceutical development. The company maintains a small catalog of bifunctional chelating agents, complexes, and reactive intermediates that support discovery and clinical research programs. Both catalog and custom products can be made using GMP, applying phase appropriate controls for raw materials and drug substances.

www.macrocyclics.com

Exhibition Partner

Perceptive Discovery bridges the gap between preclinical insights and early clinical success, delivering the expertise and high-quality data needed to advance innovation with confidence. With deep capabilities in advanced imaging, radiochemistry, and translational science, we support drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous analysis, stateof-the-art platforms, and multidisciplinary expertise to drive smarter decisions, reduce risk, and accelerate timelines from preclinical to first-in-human studies.

www.perceptive.com

Exhibition Partner

Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech. With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities. Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package: all quality and non-clinical safety data required for translation of a radiopharmaceutical.

www.chelatec.com

> "Relevant topics with cutting edge science in the field of radioligand therapy. All talks were very relevant to conference theme"
>
> *Past Attendee, Associate Director, Scientific,* **Ferring International Center**

Get Involved



Molly Biggin
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partnership Opportunities

3rd Annual TRP Target Selection & Drug Design Summit

February 23-25, 2027 | Boston, MA

Position Your Organization at the Center of Global Targeted Radiopharmaceutical Target Selection & Drug Design Experts

The **3rd TRP Target Selection & Drug Design Summit** puts your solutions and expertise in front of 100+ RLT leaders at the point where targets, technologies and development partners are being selected.

Connect with 100+ radiopharmaceutical decision-makers and technical experts while pipelines are still taking shape, build relationships ahead of future outsourcing and purchasing decisions, and position your capabilities as the solution they turn to as candidates progress towards the clinic.

The RLT industry is actively seeking expertise across **Molecular Imaging & Dosimetry**, **Preclinical & Translational Services**, **Target Discovery & Validation**, **Computational Biology, Radiochemistry & Isotope Supply**, **Chelators & Conjugation**, **PK & Biodistribution**, and **Toxicology & Non-Clinical Safety**.

Secure your place alongside leading solution providers already using the meeting to build pipeline, strengthen market visibility and become the partner of choice for the next generation of RLT programs.

Here's How You Win:

Put a Face to a Name & Make Real Connections that you can't make over email

Connect with 100+ senior decision makers across biotech, pharma, regulators, academia and more, through 20+ hours of structured networking, private meetings and informal discussions, to generate high value commercial opportunities

Attendee List Access

Gain early access to the full delegate list of discovery and preclinical attendees to schedule your 1-2-1 meetings in advance and target your onsite experience.

Data-Driven or Case Study Presentation

Share your targeting moiety & selection success stories and lessons learned to establish your team as a thought-leader in the discovery/preclinical field.

On-Site & Digital Branding & Marketing Materials

Showcase your organization prominently through strategic on-site and online branding opportunities, with tailored marketing materials to boost your visibility.

Expert Panel Participation

Join the speaker faculty as part of an early RLT development specific panel to shape forward-looking industry dialogue & position yourself as a KOL in the space, technical insights and understanding win business.

Exhibition Booth Presence

Increase your visibility and connect with prospective partners through a branded booth and merchandising.

Hosted Networking Meals & Receptions

Engage your exact target audience over hosted lunch and dinner for dedicated face-to-face time with the experts you want to meet the most

Access Early Connections With New Early-Stage Biotechs


Forge early connections with emerging companies in the audience and unlock opportunities to create networks with solution providers enabling optimized target selection & drug design.

Seniority of Attendees



- C-Suite - 28%
- Director Level - 42%
- Project Team/Manager – 26%
- Academic/Professor – 4%

Type of Companies Attending*



- Pharma
- Biotech
- Academia
- Solution Provider

*Statistics Taken from Inaugural TRP Target Selection & Drug Design Summit

Get Involved



Molly Biggin
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.targeted-radiopharma-target-selection-drug-design.com/

Tel: +1 617 455 4188

Email: info@hansonwade.com

IDENTIFY high-potential RLT targets by interrogating novel biology, mining clinically validated targets from other modalities & leveraging advanced imaging to strengthen target selection.

OPTIMIZE your radiopharmaceutical design by benchmarking target, binder, radionuclide, linker & chelator strategies to build candidates with greater therapeutic potential.

PROGRESS your program towards the clinic by strengthening preclinical, dosimetry & safety strategies and connecting with the experts shaping the next generation of RLTs.

Submit a poster to present your latest TRP breakthroughs, generate valuable discussions with industry leaders and raise the profile of your research amongst the European radiopharmaceutical community. Email info@hansonwade.com for more information.

Drug Developers	Register by Friday, November 20 & Save up to $800	On the Door Price
FULL PACKAGE: Workshop Day & Conference Days	$3,707	$4,507
Conference Only	$2,749	$3,149
Academic & Research Institutes**	Register by Friday, November 20 & Save up to $800	On the Door Price
FULL PACKAGE: Workshop Day & Conference Days	$3,107	$3,907
Conference Only	$2,349	$2,749
Solution & Service Providers	Register by Friday, November 20 & Save up to $400	On the Door Price
FULL PACKAGE: Workshop Day & Conference Days	$4,997	$5,397
Conference Only	$3,599	$3,999

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Revere Hotel Boston Common
200 Stuart Street, Boston, MA 02116, United States
www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom